<p>恩辛峯峯顧問公司在第二季度減持了碧迪醫療公司（Becton, Dickinson and Company，NYSE:BDX - Free Report）的股份，根據該公司最近向證券交易委員會（SEC）披露的信息，持有該醫療器械供應商的股票 156,408 股，比期間減持了 15,297 股。恩辛峯峯顧問公司在最近一個季度結束時持有碧迪醫療公司 0.05% 的股份，價值 3655.4 萬美元。</p>
<p>其他大型投資者最近也調整了對該公司的持股。利維斯伯格金融諮詢公司在第四季度新建了一份碧迪醫療公司的頭寸，價值約 27000 美元。OLD Point Trust &amp; Financial Services N A 在第四季度購入了碧迪醫療公司的新股，價值約 29000 美元。斯卡伯勒顧問有限責任公司在第四季度新建了一份碧迪醫療公司的頭寸，價值約 32000 美元。萊斯顧問有限責任公司在第一季度購入了碧迪醫療公司的新頭寸，價值約 38000 美元。最後，ICA 集團財富管理有限責任公司在第四季度購入了碧迪醫療公司的新股，價值約 42000 美元。86.97% 的股份由機構投資者持有。</p>
<h2>分析師的升級和降級</h2>
<p>幾位研究分析師對 BDX 股票發表了意見。StockNews.com 在 8 月 8 日星期四的一份研究報告中，將碧迪醫療公司的評級從 “持有” 調升至 “買入”。高盛集團在 5 月 30 日星期四對碧迪醫療公司的股票進行了覆蓋。他們給出了一份 “買入” 評級和 274.00 美元的價格目標。雷蒙德詹姆斯將碧迪醫療公司的目標股價從 275.00 美元降至 270.00 美元，並在 8 月 2 日星期五的一份研究報告中給出了 “表現優異” 的評級。花旗集團將碧迪醫療公司的股票價格目標從 260.00 美元降至 255.00 美元，並在 7 月 10 日星期三的一份研究報告中為該公司設定了 “中性” 評級。最後，斯蒂弗爾尼古拉斯將碧迪醫療公司的股票價格目標從 270.00 美元上調至 280.00 美元，並在 7 月 26 日星期五的一份研究報告中給出了 “買入” 評級。一位股票研究分析師給出了持有評級，而八位則給出了買入評級。根據 MarketBeat.com 的數據，碧迪醫療公司目前的共識評級為 “中等買入”，平均目標股價為 279.50 美元。</p>
<p><strong>查看我們對碧迪醫療公司的最新報告</strong></p>
<h2>碧迪醫療公司股價下跌 0.5%</h2>
<p>紐約證券交易所（NYSE）BDX 週五開盤價為 233.50 美元。該公司的 50 天移動平均股價為 235.51 美元，200 天移動平均股價為 235.54 美元。該股的市值為 674.8 億美元，市盈率為 51.43，PEG 比率為 1.91，貝塔係數為 0.42。碧迪醫療公司的 52 周最低價為 218.75 美元，最高價為 269.52 美元。該公司的資產負債比為 0.70，流動比率為 1.85，速動比率為 1.36。</p>
<p>碧迪醫療公司（NYSE:BDX - Get Free Report）於 8 月 1 日星期四公佈了季度財報。該醫療器械供應商在該季度報告中每股盈利 3.50 美元，超過了市場預期的 3.31 美元，增加了 0.19 美元。該季度業務收入為 49.9 億美元，低於市場預期的 50.8 億美元。碧迪醫療公司的淨資產收益率為 14.49%，淨利潤率為 7.13%。相比去年同期，碧迪醫療公司的季度收入增長了 2.3%。分析師預計，碧迪醫療公司本財年的每股收益將達到 13.1 美元。</p>
<h2>碧迪醫療公司宣佈股息</h2>
<p>該公司最近宣佈了季度股息，將於 9 月 30 日星期一支付。股東登記日為 9 月 9 日星期一，將支付 0.95 美元的股息。除息日為 9 月 9 日星期一。這代表年化股息為 3.80 美元，股息率為 1.63%。碧迪醫療公司的派息比率目前為 83.70%。</p>
<h2>碧迪醫療公司簡介（免費報告）</h2>
<p>碧迪醫療公司在全球範圍內為醫療機構、醫生、生命科學研究人員、臨牀實驗室、製藥行業和普通公眾開發、製造和銷售醫療用品、設備、實驗室設備和診斷產品。該公司分為 BD Medical、BD Life Sciences 和 BD Interventional 三個部門運營。</p>
<h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票，比碧迪醫療公司更好</li>
<li>什麼是 FAANG 股票，它們是好投資嗎？</li>
<li>利用村莊農場股票，隨着大麻市場的發展</li>
<li>比較和交易高市盈率股票</li>
<li>MarketBeat 周評 - 9/16 - 9/20</li>
<li>投資咖啡的三種方式，除了喝</li>
<li>秋季收益不容錯過的 3 只零售股</li>
</ul>
<p><strong>想看看其他對 BDX 持股的對沖基金？</strong> 訪問 HoldingsChannel.com 獲取最新的 13F 申報和內部交易信息，瞭解碧迪醫療公司（NYSE:BDX - Free Report）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJEWA"/></p>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 這個價值 15 美元的&#34;內幕秘密&#34;可能拯救您的退休金（來自市場幕後）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx"/></p>
<h2>現在是否值得投資 1,000 美元到碧迪醫療？</h2>
<p>在您考慮是否投資碧迪醫療之前，您應該聽聽這個消息。</p>
<p>MarketBeat 持續追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票... 而碧迪醫療並不在名單上。</p>
<p>儘管碧迪醫療目前在分析師中擁有&#34;中等買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

碧迪醫療

<p>Ensign Peak Advisors Inc 在第二季度減持了碧迪醫療（Becton, Dickinson and Company，NYSE:BDX）8.9％的股份，現持有 156,408 股，價值約為$554,000。該公司已經看到多家機構投資者調整其持股。分析師們給予 BDX 股票 “中等買入” 的共識評級，平均目標價為$250.50。碧迪醫療報告第二季度每股盈利為$1.50，超出預期，並宣佈每股$0.95 的季度股息，將於 9 月 30 日支付</p>

<p>Ensign Peak Advisors Inc reduced its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 8.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 156,408 shares of the medical instruments supplier's stock after selling 15,297 shares during the period. Ensign Peak Advisors Inc owned 0.05% of Becton, Dickinson and Company worth $36,554,000 at the end of the most recent quarter.</p>
<ul>
<li>Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs</li>
</ul>
<div class="lb-trans"><p>恩辛峯峯顧問公司在第二季度減持了碧迪醫療公司（Becton, Dickinson and Company，NYSE:BDX - Free Report）的股份，根據該公司最近向證券交易委員會（SEC）披露的信息，持有該醫療器械供應商的股票 156,408 股，比期間減持了 15,297 股。恩辛峯峯顧問公司在最近一個季度結束時持有碧迪醫療公司 0.05% 的股份，價值 3655.4 萬美元。</p>
</div><p>Other large investors also recently modified their holdings of the company. Livelsberger Financial Advisory acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at about $27,000. OLD Point Trust &amp; Financial Services N A bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth approximately $29,000. Scarborough Advisors LLC acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $32,000. Rise Advisors LLC bought a new position in shares of Becton, Dickinson and Company during the first quarter worth approximately $38,000. Finally, ICA Group Wealth Management LLC acquired a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $42,000. 86.97% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投資者最近也調整了對該公司的持股。利維斯伯格金融諮詢公司在第四季度新建了一份碧迪醫療公司的頭寸，價值約 27000 美元。OLD Point Trust &amp; Financial Services N A 在第四季度購入了碧迪醫療公司的新股，價值約 29000 美元。斯卡伯勒顧問有限責任公司在第四季度新建了一份碧迪醫療公司的頭寸，價值約 32000 美元。萊斯顧問有限責任公司在第一季度購入了碧迪醫療公司的新頭寸，價值約 38000 美元。最後，ICA 集團財富管理有限責任公司在第四季度購入了碧迪醫療公司的新股，價值約 42000 美元。86.97% 的股份由機構投資者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師的升級和降級</h2>
</div><p>Several research analysts have weighed in on BDX shares. StockNews.com upgraded Becton, Dickinson and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Thursday, August 8th. The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a &#34;buy&#34; rating and a $274.00 price objective for the company. Raymond James decreased their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an &#34;outperform&#34; rating on the stock in a research report on Friday, August 2nd. Citigroup dropped their price target on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a &#34;neutral&#34; rating for the company in a research report on Wednesday, July 10th. Finally, Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, July 26th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $279.50.</p>
<ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><p>幾位研究分析師對 BDX 股票發表了意見。StockNews.com 在 8 月 8 日星期四的一份研究報告中，將碧迪醫療公司的評級從 “持有” 調升至 “買入”。高盛集團在 5 月 30 日星期四對碧迪醫療公司的股票進行了覆蓋。他們給出了一份 “買入” 評級和 274.00 美元的價格目標。雷蒙德詹姆斯將碧迪醫療公司的目標股價從 275.00 美元降至 270.00 美元，並在 8 月 2 日星期五的一份研究報告中給出了 “表現優異” 的評級。花旗集團將碧迪醫療公司的股票價格目標從 260.00 美元降至 255.00 美元，並在 7 月 10 日星期三的一份研究報告中為該公司設定了 “中性” 評級。最後，斯蒂弗爾尼古拉斯將碧迪醫療公司的股票價格目標從 270.00 美元上調至 280.00 美元，並在 7 月 26 日星期五的一份研究報告中給出了 “買入” 評級。一位股票研究分析師給出了持有評級，而八位則給出了買入評級。根據 MarketBeat.com 的數據，碧迪醫療公司目前的共識評級為 “中等買入”，平均目標股價為 279.50 美元。</p>
</div><p><strong>View Our Latest Report on Becton, Dickinson and Company</strong></p>
<div class="lb-trans"><p><strong>查看我們對碧迪醫療公司的最新報告</strong></p>
</div><h2>Becton, Dickinson and Company Stock Down 0.5 %</h2>
<div class="lb-trans"><h2>碧迪醫療公司股價下跌 0.5%</h2>
</div><p>NYSE BDX opened at $233.50 on Friday. The business has a fifty day moving average price of $235.51 and a two-hundred day moving average price of $235.54. The stock has a market capitalization of $67.48 billion, a PE ratio of 51.43, a PEG ratio of 1.91 and a beta of 0.42. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $269.52. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.</p>
<div class="lb-trans"><p>紐約證券交易所（NYSE）BDX 週五開盤價為 233.50 美元。該公司的 50 天移動平均股價為 235.51 美元，200 天移動平均股價為 235.54 美元。該股的市值為 674.8 億美元，市盈率為 51.43，PEG 比率為 1.91，貝塔係數為 0.42。碧迪醫療公司的 52 周最低價為 218.75 美元，最高價為 269.52 美元。該公司的資產負債比為 0.70，流動比率為 1.85，速動比率為 1.36。</p>
</div><p>Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company's revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.96 EPS. Equities analysts expect that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>碧迪醫療公司（NYSE:BDX - Get Free Report）於 8 月 1 日星期四公佈了季度財報。該醫療器械供應商在該季度報告中每股盈利 3.50 美元，超過了市場預期的 3.31 美元，增加了 0.19 美元。該季度業務收入為 49.9 億美元，低於市場預期的 50.8 億美元。碧迪醫療公司的淨資產收益率為 14.49%，淨利潤率為 7.13%。相比去年同期，碧迪醫療公司的季度收入增長了 2.3%。分析師預計，碧迪醫療公司本財年的每股收益將達到 13.1 美元。</p>
</div><h2>Becton, Dickinson and Company Dividend Announcement</h2>
<div class="lb-trans"><h2>碧迪醫療公司宣佈股息</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a $0.95 dividend. The ex-dividend date is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. Becton, Dickinson and Company's payout ratio is currently 83.70%.</p>
<div class="lb-trans"><p>該公司最近宣佈了季度股息，將於 9 月 30 日星期一支付。股東登記日為 9 月 9 日星期一，將支付 0.95 美元的股息。除息日為 9 月 9 日星期一。這代表年化股息為 3.80 美元，股息率為 1.63%。碧迪醫療公司的派息比率目前為 83.70%。</p>
</div><h2>Becton, Dickinson and Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>碧迪醫療公司簡介（免費報告）</h2>
</div><p>Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.</p>
<div class="lb-trans"><p>碧迪醫療公司在全球範圍內為醫療機構、醫生、生命科學研究人員、臨牀實驗室、製藥行業和普通公眾開發、製造和銷售醫療用品、設備、實驗室設備和診斷產品。該公司分為 BD Medical、BD Life Sciences 和 BD Interventional 三個部門運營。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Becton, Dickinson and Company</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Take Advantage of Village Farms Stock as Cannabis Market Evolves</li>
<li>Comparing and Trading High PE Ratio Stocks</li>
<li>MarketBeat Week in Review – 9/16 - 9/20</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>Don’t Miss These 3 Retail Stocks for Fall Gains</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票，比碧迪醫療公司更好</li>
<li>什麼是 FAANG 股票，它們是好投資嗎？</li>
<li>利用村莊農場股票，隨着大麻市場的發展</li>
<li>比較和交易高市盈率股票</li>
<li>MarketBeat 周評 - 9/16 - 9/20</li>
<li>投資咖啡的三種方式，除了喝</li>
<li>秋季收益不容錯過的 3 只零售股</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BDX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 BDX 持股的對沖基金？</strong> 訪問 HoldingsChannel.com 獲取最新的 13F 申報和內部交易信息，瞭解碧迪醫療公司（NYSE:BDX - Free Report）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJEWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ The $15 &#34;Insider Secret&#34; That Could Save Your Retirement (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 這個價值 15 美元的&#34;內幕秘密&#34;可能拯救您的退休金（來自市場幕後）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9451&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Becton, Dickinson and Company right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1,000 美元到碧迪醫療？</h2>
</div><p>Before you consider Becton, Dickinson and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮是否投資碧迪醫療之前，您應該聽聽這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 持續追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票... 而碧迪醫療並不在名單上。</p>
</div><p>While Becton, Dickinson and Company currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管碧迪醫療目前在分析師中擁有&#34;中等買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Ensign Peak Advisors Inc 在碧迪醫療公司（NYSE: BDX）持有 3655 萬美元的股票